...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Progress in Cardiovascular Diseases >New antiarrhythmic drugs for prevention of atrial fibrillation.
【24h】

New antiarrhythmic drugs for prevention of atrial fibrillation.

机译：预防房颤的新型抗心律失常药物。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Enhanced understanding of the mechanisms underlying atrial fibrillation (AF) and advent of catheter-based therapy for AF has altered the approach to patients with this most common arrhythmia. However, despite the success of aggressive procedural techniques, pharmacologic therapy remains the first-line and mainstay approach in the treatment of AF. This review of new antiarrhythmic drug (AAD) therapy for AF provides an in-depth overview of recently available classic and new investigational drugs being considered for AF treatment. Currently available AADs are associated with less than satisfactory efficacy in preventing AF and a significant side effect profile, including ventricular proarrhythmia. Recent investigations have focused on development of new AADs that, hopefully, will be more effective and safer even in patients with structural heart disease. These new AADs include selective multi-ion channel and atrial specific blockers and agents that target the underlying etiologies and substrate alterations that lead to AF. Included among the latter new category are agents that suppress activation of the renin-angiotensin-aldosterone system or inflammation, which represent novel targets for drug therapy for AF. Finally, new selective A1 adenosine receptor agonists may offer the possibility of more specific and successful ventricular rate control during AF. There is considerable hope and interest that improved understanding of AF mechanisms ultimately will result in more effective and less dangerous pharmacologic therapy becoming available in the future.
机译：对房颤（AF）的基本机制的进一步了解以及针对AF的基于导管的治疗的出现改变了这种最常见的心律不齐患者的治疗方法。然而，尽管积极的手术技术取得了成功，但药物治疗仍是房颤治疗的第一线和主要方法。这项针对房颤的新抗心律失常药物（AAD）治疗的综述提供了有关正在考虑用于房颤治疗的经典药物和新研究药物的深入概述。当前可用的AAD与预防AF的效果不令人满意以及包括室性心律失常在内的明显副作用有关。最近的研究集中在新AAD的开发上，希望即使在患有结构性心脏病的患者中，AAD也会更加有效和安全。这些新的AAD包括选择性的多离子通道和特定于心房的阻滞剂，以及针对导致AF的潜在病因和底物改变的药物。后者中包括抑制肾素-血管紧张素-醛固酮系统激活或炎症的药物，这些药物代表了房颤药物治疗的新靶标。最后，新的选择性A1腺苷受体激动剂可能为房颤期间更特异性和成功的心室率控制提供可能性。有很大的希望和兴趣，对AF机制的更好理解最终将导致将来更有效，更危险的药物治疗成为可能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号